Clinical Trials

  • Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.

    Trial setback casts doubt on a biotech's respiratory virus drug

    As vaccines for respiratory syncytial virus progressed, Enanta used its hepatitis C know-how to develop an antiviral pill. Yet data in lower-risk patients raise questions of whether it can work.

    By May 19, 2022
  • Image attribution tooltip
    Danielle Ternes/BioPharma Dive

    Scientists home in on cause of Duchenne gene therapy side effect

    An unusual collaboration among gene therapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.

    By Updated May 18, 2022
  • Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead, having resolved manufacturing issues, forges ahead with HIV drug

    The company can now resume testing in nearly a dozen studies that were paused due to FDA concerns about interactions between the drug, lenacapavir, and the glass vials in which it was contained.

    By May 17, 2022
  • Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers' Opdivo comes up short in bladder cancer trial

    The top-selling immunotherapy failed to improve survival in first-line urothelial carcinoma, a tumor type that's proved difficult to treat with drugs like Opdivo.

    By May 16, 2022
  • Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Key Bristol Myers drug holds up in long-term psoriasis study

    Deucravacitnib, forecast by Bristol Myers to hit $4 billion in peak sales, is under FDA review with an approval decision due by September. The agency's view of its safety will be key to its future.

    By May 12, 2022
  • Image attribution tooltip
    Permission granted by Sekar Kathiresan

    In first, Verve gets clearance to test base editing inside the body

    Regulators in New Zealand have allowed human testing to proceed, another milestone for the gene editing technology. Verve plans to soon ask for approval to begin testing in the U.S. and U.K., too. 

    By Kristin Jensen • May 11, 2022
  • Image attribution tooltip
    iStock via Getty Images

    Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

    A treatment combination involving Roche's anti-TIGIT medicine tiragolumab missed its goal in a Phase 3 lung cancer study that was viewed as a proof point for the drug class.

    By May 11, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic

    The companies' hepatitis B program never reached clinical testing, while J&J said it would no longer develop an HPV vaccine because of the "widespread uptake" of effective shots from other companies.

    By May 9, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Argenx drug succeeds in trial, beats sales forecasts

    The biotech reported positive results from a study meant to expand Vyvgart's use to another immune disorder, while sales from the drug's first quarter on the market exceeded expectations.

    By Kristin Jensen • May 5, 2022
  • Image attribution tooltip
    libre de droit via Getty Images

    Pfizer cleared to restart hemophilia gene therapy trial

    While a voluntary pause in dosing new patients will remain in place, the FDA's decision puts the study back on track to deliver data in 2023.

    By May 3, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA rejects two China-developed cancer drugs

    The regulator cited concerns around single-country trials in turning back Hutchmed's pancreatic cancer treatment, while manufacturing issues held up Junshi and Coherus' throat cancer medicine.

    By May 2, 2022
  • Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex surprised by FDA halt of diabetes cell therapy study

    The regulator determined Vertex had "insufficient information" to test higher doses of the therapy, which showed promise in the first two patients treated.

    By May 2, 2022
  • Image attribution tooltip
    DNY59 via Getty Images

    Ionis, AstraZeneca change a key trial, fueling more questions about a genetic heart disease

    The partners increased the size and length of a large study in transthyretin amyloidosis cardiomyopathy, a decision that has implications for Alnylam, which is testing two of its drugs for the disease. 

    By May 2, 2022
  • Lilly's closely watched diabetes drug scores in obesity trial

    Called tirzepatide, the drug significantly lowered weight loss in a large study, findings that add to growing evidence that a class of medicines originally meant for diabetes may effectively treat obesity.

    By April 28, 2022
  • Image attribution tooltip
    Courtesy of Roche

    Roche stumbles in latest setback for an emerging group of breast cancer drugs

    The Phase 2 failure marks the second negative result in two months for a closely watched group of medicines, known as SERDs, that are being developed by several large pharmaceutical companies.

    By April 25, 2022
  • Image attribution tooltip
    Jolygon via Getty Images

    How a surprise finding made an Alnylam study one of biotech's most 'polarizing' trials

    A study testing Alnylam's drug Onpattro in a deadly heart condition was once seen as a sure bet. Now the trial is the source of much debate, and its outcome could influence how future treatments for the disease are developed.

    By April 25, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA panel supports agency push to raise approval bar for certain cancer drugs

    Though agency advisers were hesitant to label an entire drug class, they backed the FDA's interest in demanding randomized trials of PI3 kinase-blocking drugs, a decision that could impact future research.

    By April 22, 2022
  • Bristol Myers scraps $2B Nektar partnership after trial failures

    The companies have halted testing in kidney and bladder cancer, one month after ending a skin cancer study. Nektar executives are now preparing plans to conserve cash.

    By April 18, 2022
  • Image attribution tooltip

    AbbVie, Genmab, with new data, prep FDA application for dual-acting cancer drug

    Fresh trial results intensify competition with Roche to deliver the first lymphoma drug that marries antibody technology with an immunotherapy pathway.

    By April 14, 2022
  • Image attribution tooltip
    Justin Sullivan via Getty Images

    FDA clears Gilead to restart some studies of top cancer drug

    The agency's OK is a needed reprieve for Gilead, whose dealmaking strategy in oncology has come under scrutiny from analysts and investors.

    By April 12, 2022
  • Image attribution tooltip
    BioPharma Dive

    AACR 2022: NK cell promise, more TIGIT questions and extending CAR-T's reach

    This year's meeting on early cancer research featured promising study results from German biotechs BioNTech and Affimed as well as details from a "practice-changing" lung cancer trial.

    By , April 11, 2022
  • Image attribution tooltip
    William Walker/BioPharma Dive
    Sponsored by Janssen Oncology

    [Podcast] Breaking Down Barriers: How Bladder Cancer Innovations Benefit Patients and Treatments for Other Diseases

    Recent breakthroughs in bladder cancer treatment are helping patients combat one major challenge to current options — the bladder permeability barrier. These treatments also have implications for other cancers and diseases. This podcast explains how.

    By BioPharma Dive's studioID • April 11, 2022
  • Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex gets positive trial results for non-opioid painkiller in boost to pipeline

    After several attempts at designing a drug for acute pain, Vertex has a candidate it's ready to take into late-stage testing following two successful Phase 2 studies.

    By March 31, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    ALS drug development

    FDA advisers narrowly side against an experimental ALS drug, likely lowering its approval chances

    The panel of independent experts found clinical trial evidence generated by the drug's developer, Amylyx Pharmaceuticals, insufficient to establish the treatment's effectiveness.

    By Updated March 30, 2022
  • Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.

    Adagio plans comeback for COVID drug, but is it too late?

    The biotech said it will ask the FDA for approval of its antibody treatment after positive results from two trials. But relatively few participants were exposed to omicron, potentially raising questions about its utility.

    By March 30, 2022